Publikationen 2013

94. Schlenk RF, Döhner H.  Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia.  Hematology Am Soc Hematol Educ Program. 2013;2013:324-30.

93.  Paschka P, Döhner K.  Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?  Hematology Am Soc Hematol Educ Program. 2013;2013:209-19.

92.  Schittenhelm MM, Illing B, Ahmut F, Rasp KH, Blumenstock G, Döhner K, Lopez CD, Kampa-Schittenhelm KM.  Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure.  PLoS One. 2013 Nov 27;8(11):e80193.

91.  Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rübe C, Zwick C, Glass B, Schmitz N, Pfreundschuh M.  Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement.  J Clin Oncol. 2013 Nov 10;31(32):4115-22.

90.  Gerull S, Stern M, Apperley J, Beelen D, Brinch L, Bunjes D, Butler A, Ganser A, Ghavamzadeh A, Koh MB, Komarnicki M, Kröger N, Maertens J, Maschan A, Peters C, Rovira M, Sengeløv H, Socie' G, Tischer J, Oneto R, Passweg J, Marsh J.  Syngeneic transplantation in aplastic anemia: pretransplant conditioning and peripheral blood are associated with improved engraftment - an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation.  Haematologica. 2013 Nov;98(11):1804-9.

89.  Höffken G1, Kern P, Buchholz U, Ewig S, Schaberg T.  [Informations and recommendations of the German Respiratory Society and the Paul-Ehrlich-Society for chemotherapy concerning the outbreak of influenza A(H7N9) virus infections in humans]. [Article in German]  Pneumologie. 2013 Nov;67(11):599-604.

88.  Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M; ESMO Guidelines Working Group.  Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2013 Oct;24 Suppl 6:vi155-9. No abstract available.

87.  Fey MF, Buske C; ESMO Guidelines Working Group.  Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2013 Oct;24 Suppl 6:vi138-43. Epub 2013 Aug 22. No abstract available.

86.  Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F.  Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter Syndrome.  Blood. 2013 Oct 10;122(15):2673-82.

85.  Fürst D, Müller C, Vucinic V, Bunjes D, Herr W, Gramatzki M, Schwerdtfeger R, Arnold R, Einsele H, Wulf G, Pfreundschuh M, Glass B, Schrezenmeier H, Schwarz K, Mytilineos J.  High resolution HLA-matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.  Blood. 2013 Oct 31;122(18):3220-9.

84.  Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, McDonald EJ, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat J, Boultwood J.  Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.  J Clin Oncol. 2013 Oct 1;31(28):3557-64.

83.  Meilinger M, Stoeckl C, Pollheimer M, Kern P, Reisinger EC, Seeber K, Krause R, Flick H, Hoenigl M.  Progressive alveolar echinococcosis after discontinuation of anthelmintic therapy.  Parasit Vectors. 2013 Oct 1;6(1):287.

82.  Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H.  A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.  Br J Haematol. 2013 Oct;163(2):214-222.

81.  Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JAL, Neben K, Hoffmann P, Nöthen M, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H.  Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.  Nat Genet 2013 Oct;45(10):1221-5.

80.  Ringhoffer S, Rojewski M, Döhner H, Bunjes D, Ringhoffer M.  T cell reconstitution after allogeneic stem cell transplantation: assessment by the measurement of the sjTREC/βTREC-ratio and thymic naive T cells.  Haematologica. 2013 Oct;98(10):1600-1608.

79.  Wahlers K, Menezes CN, Romig T, Kern P, Grobusch MP.  Cystic echinoccosis in South Africa: the worst yet to come?  Acta Trop. 2013 Oct;128(1): 1-6.

78.  Kaasch AJ1, Rieg S, Kuetscher J, Brodt HR, Widmann T, Herrmann M, Meyer C, Welte T, Kern P, Haars U, Reuter S, Hübner I, Strauss R, Sinha B, Brunkhorst FM, Hellmich M, Fätkenheuer G, Kern WV, Seifert H; preSABATO study group.  Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study.  Infection. 2013 Oct;41(5):979-85.

77.  Iolascon A1, Heimpel H, Wahlin A, Tamary H.  Congenital dyserythropoietic anemias: molecular insights and diagnostic approach.  Blood. 2013 Sep 26;122(13):2162-6.   76.  Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud O.  CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia.  Oncotarget. 2013 Sep;4(9):1438-48.

75.  Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M, Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ, Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C.  Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change.  J Clin Oncol. 2013 Sep 10;31(26):3259-3271.

74.  Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R and  Hallek M.  Prediction of poor outcome in CLL patients following first-line 2 treatment with fludarabine, cyclophosphamide and rituximab.  Leukemia. 2013 Sep;27(9):1949-52.

73.  Mogoye BK1, Menezes CN, Wong ML, Stacey S, von Delft D, Wahlers K, Wassermann M, Romig T, Kern P, Grobusch MP, Frean J.  First insights into species and genotypes of Echinococcus in South Africa.  Vet Parasitol. 2013 Sep 23;196(3-4):427-32.

72.  Piechnik A, Dmoszynska A, Omiotek M, Mlak R, Kowal M, Stilgenbauer S, Bullinger L, Giannopoulos K.  The VEGF receptor, neuropilin-1 (NRP1) represents a promising novel target for chronic lymphocytic leukemia patients.  Int J Cancer. 2013 Sep 15;133(6):1489-96.

71.  Thoden J1, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Härter G, Hartmann M, Herzmann C, Hutterer J, Jordan AR, Lange C, Mauss S, Meyer-Olson D, Mosthaf F, Oette M, Reuter S, Rieger A, Rosenkranz T, Ruhnke M, Schaaf B, Schwarze S, Stellbrink HJ, Stocker H, Stoehr A, Stoll M, Träder C, Vogel M, Wagner D, Wyen C, Hoffmann C.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).  Infection. 2013 Sep;41 Suppl 2:S91-115.

70.  Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG  A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies  Leuk Res. 2013 Sep;37(9):1100-6.

69.  Göbel M, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J.  Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.  PLoS One. 2013 Aug 23;8(8):e72107.   68.  Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B.  The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.  Blood. 2013 Aug 29;122(9):1576-82.

67.  Göbel M1, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J.  Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.  PLoS One. 2013 Aug 23;8(8):e72107. eCollection 2013.

66.  Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S.  NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.  Blood. 2013 Aug 15;122(7):1266-70.

65.  Greiner J, Schneider V, Schmitt M, Götz M, Döhner K, Wiesneth M, Döhner H, Hofmann S..  Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).  Blood. 2013 Aug 8;122(6):1087-8.

64.  Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA.  Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma.  N Engl J Med. 2013 Aug 8;369(6):507-16.

63.  Copley MR1, Babovic S, Benz C, Knapp DJ, Beer PA, Kent DG, Wohrer S, Treloar DQ, Day C, Rowe K, Mader H, Kuchenbauer F, Humphries RK, Eaves CJ.  The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells.  Nat Cell Biol. 2013 Aug;15(8):916-25

62.  Dickson GJ, Liberante FG, Kettyle LM, O'Hagan K, Finnegan DP, Bullinger L, Geerts D, McMullin MF, Lappin TR, Mills KI, Thompson A.  HOXA/PBX3 knockdown impairs growth and sensitizes Cytogenetically Normal AML cells to chemotherapy.  Haematologica. 2013 Aug;98(8):1216-25.

61.  Hüllein J, Jethwa A, Stolz T, Blume C, Sellner L, Sill M, Langer C, Jauch A, Paruzynski A, von Kalle C, Schmidt M, Glimm H, Zenz T.  Next-generation sequencing of cancer consensus genes in lymphoma.  Leuk Lymphoma 2013 Aug;54(8):1831-5.

60.  te Raa GD1, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).  Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.  Leuk Lymphoma. 2013 Aug;54(8):1849-53.

59.  Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner C, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F, Döhner H, Stigenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K.  Second-line Therapies of Patients initially treated with Fludarabine and Cyclophosphamide (FC) or Fludarabine, Cyclophosphamide and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG).  Leuk Lymphoma. 2013 Aug;54(8):1821-2.

58.  Kugler SJ, Schnaiter A, Stilgenbauer S, Mertens D.  Missing the Notch in NOTCH1.  Leuk Lymphoma. 2013 Aug;54(8):1579-80. No abstract available.

57.  Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Dreyling M, Bohlander SK.  High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.  Leuk Lymphoma. 2013 Aug;54(8):1652-7.

56.  Haderk F, Hanna B, Richter K, Schnölzer M, Zenz T, Stilgenbauer S, Lichter P, Seiffert M.  Extracellular vesicles in chronic lymphocytic leukemia.  Leuk Lymphoma. 2013 Aug;54(8):1826-1830.

55.  Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D.  Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study.  Leuk Res. 2013 Aug;37(8):900-6.

54.  Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Lee SJ, Horowitz MM, Greenberg PL, Tallman MS, Dipersio JF, Bunjes D, Weisdorf DJ, Cutler C.  Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis.  J Clin Oncol. 2013 Jul 20;31(21):2662-70.

53.  Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto, the German–Austrian Acute Myeloid Leukemia Study Group, and Study Alliance Leukemia.  Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia.  N Engl J Med. 2013 Jul 11;369(2):111-121.

52.  Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwoerer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K.  Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia.  Blood. 2013 Jul 4;122(1):100-8.

51.  Schneider V, Egenrieder S, Götz M, Herbst C, Greiner J, Hofmann S.  Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.  Leuk Lymphoma. 2013 Jul;54(7):1500-4.

50.  Blijlevens N1, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D; CLWP of the EBMT. Angelucci E, Benboubker L, Blijlevens N, Browne P, Bourhis JH, Bunjes D, Carella AM, Crawley C, Christiansen I, Clausen J, Dreger P, Einsele H, Cook G, Cook M, Facon T, Fillitz M, Garderet L, Gratwohl A, Harrousseau JL, Iacopino P, Melacrino AO, Jebavy L, Kralove H, Johansson JE, Kasparu H, Ketterer N, Kienast J, Kobbe G, Krivan G, Deliliers GL, Lemoli RM, Linkesch W, Losonczy H, Maertens J, Lutz D, Meloni G, Masszi T, Morgan G, Niederwieser D, Pytlik R, Rabitsch W, Rahemtulla A, Rossi JF, Russell N, Ruutu T, Saglio G, Sonet A, Szomor A, Van Droogenbroeck PH, Zachee P.  In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.  Bone Marrow Transplant. 2013 Jul;48(7):966-71.

49.  Stolze B, Scholl C.  [Exploiting functional dependencies in cancer cells for the development of targeted therapies]  Dtsch Med Wochenschr 138:1369-1372, 2013. Article in German.

48.  Wu Y, Ihme S, Feuring-Buske M, Kuan SL, Eisele K, Lamla M, Wang Y, Buske C, Weil T.  A Core-Shell Albumin Copolymer Nanotransporter for High Capacity Loading and Two-Step Release of Doxorubicin with Enhanced Anti-Leukemia Activity.  Adv Healthc Mater. 2013 Jun;2(6):884-94.

47.  Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D, Kuchenbauer F.  Circulating microRNAs in hematological diseases: principles, challenges and perspectives.  Blood. 2013 Jun 20;121(25):4977-84.

46.  Zwick C, Fadle N, Regitz E, Kemele M, Stilgenbauer S, Bühler A, Pfreundschuh M, Preuss KD.  Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells.  Blood. 2013 Jun 6;121(23):4708-17.

45.  Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, and Döhner K.  Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)  Blood. 2013 Jun 6;121(23):4769-77.

44.  Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M.  Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.  Cancer. 2013 Jun 15;119(12):2258-67.

43.  Jebaraj BM, Kienle D, Bühler A, Winkler D, Döhner H, Stilgenbauer S, Zenz T.  BRAF mutations in Chronic Lymphocytic Leukemia.  Leuk Lymphoma. 2013 Jun;54(6):1177-82.

42.  Basak GW, de Wreede LC, van Biezen A, Wiktor-Jedrzejczak W, Schmid C, Schattenberg A, Dazzi F, von dem Borne P, Petersen E, Beelen D, Abayomi A, Volin L, Buzyn A, Gurman G, Bunjes D, Olavarria E, de Witte T, Chronic Leukemia Working Party EBM  Donor lymphocyte infusions for the treatment of chronic myelogenous leukaemia relapse following peripheral blood or bone marrow stem cell transplantation.  Bone Marrow Transplant. 2013 Jun;48(6):837-42.

41.  Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken JC, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks C, Wang W, Döhner K, Jansen JH, Pahl HL.  MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.  J Exp Med. 2013 May 6;210(5):1003-19.

40.  Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J.  Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.  Mycoses. 2013 May;56(3):304-10.

39.  Binder H, Benner A, Bullinger L, Schumacher M.  Tailoring sparse multivariable regression techniques for prognostic single-nucleotide polymorphism signatures.  Stat Med. 2013 May 10;32(10):1778-91.

38.  Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.  Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.  Mol Cancer. 2013 May 24;12(1):46.

37.  Bullinger L, Schlenk RF, Goetz M, Botzenhardt U, Hofmann S, Russ AC, Babiak A, Zhang L, Schneider V, Dohner K, Schmitt M, Dohner H, Greiner J.  PRAME induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17).  Clin Cancer Res. 2013 May 1;19(9):2562-71.

36.  Kumar M1, Witt B, Knippschild U, Koch S, Meena JK, Heinlein C, Weise JM, Krepulat F, Kuchenbauer F, Iben S, Rudolph KL, Deppert W, Günes C.  CEBP factors regulate telomerase reverse transcriptase promoter activity in whey acidic protein-T mice during mammary carcinogenesis.  Int J Cancer. 2013 May 1;132(9):2032-43.

35.  Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S.  TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.  Blood. 2013 Apr 18;121(16):3284-8.

34.  Krivtsov AV, Figueroa ME, Sinha AU,Stubbs MC, Feng Z, Valk PJM, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA.  Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.  Leukemia. 2013 Apr;27(4):852-60.

33.  Garding A, Bhattacharya N, Claus R, Ruppel M, Tschuch C, Filarsky K, Idler I, Zucknick M, Caudron-Herger M, Oakes C, Fleig V, Keklikoglou I, Allegra D, Serra L, Thakurela S, Tiwari V, Weichenhan D, Benner A, Radlwimmer B, Zentgraf H, Wiemann S, Rippe K, Plass C, Döhner H, Lichter P, Stilgenbauer S, Mertens D.  Epigenetic Upregulation of lncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB.  PLoS Genet. 2013 Apr;9(4):e1003373.

32.  Schnaiter A, Stilgenbauer S.  17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.  Hematol Oncol Clin North Am. 2013 Apr;27(2):289-301.

31.  Pfeiffer T, Schleuning M, Mayer J, Haude KH, Tischer J, Buchholz S, Bunjes D, Bug G, Holler E, Meyer RG, Greinix H, Scheid C, Christopeit M, Schnittger S, Braess J, Schlimok G, Spiekermann K, Ganser A, Kolb HJ, Schmid C.  Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.  Haematologica. 2013 Apr;98(4):518-25.

30.  Richter D1, Richter J, Grüner B, Kranz K, Franz J, Kern P.  In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.  Parasitol Res. 2013 Apr;112(4):1655-60.

29.  Langer C, Rücker FG, Buske C, Döhner H, Kuchenbauer F.  Targeted therapies through microRNAs: pulp or fiction?  Ther Adv Hematol. 2012 Apr;3(2):97-104.

28.  van Vliet MH, Dumee B, Simons E, Bullinger L, Döhner K, Döhner H, Viëtor H, Löwenberg B, Valk PJ, van Beers EH.  Detection of Mutant NPM1 mRNA in Acute Myeloid Leukemia Using Custom Gene Expression Arrays.  Genet Test Mol Biomarkers. 2013 Apr;17(4):295-300.

27.  Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).  Ann Oncol. 2013 Mar;24(3):561-76.

26.  Li Z, Herold T, He C, Valk PJM, Chen P, Jurinovic V, Mansmann U, Radmacher M, Maharry K, Sun M, Yang X, Huang H, Jiang X, Sauerland M, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen J.  Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study of 1,324 Patients.  J Clin Oncol. 2013 Mar 20;31(9):1172-81.

25.  Schulz A, Dürr C, Zenz T, Döhner H, Stilgenbauer S, Lichter P, Seiffert M.  Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary co-cultures by altering the myeloid microenvironment.  Blood. 2013 Mar 28;121(13):2503-11.

24.  Diffner E, Beck D, Gudgin E, Thoms JA, Knezevic K, Pridans C, Foster S, Goode D, Lim WK, Boelen L, Metzeler KH, Micklem G, Bohlander SK, Buske C, Burnett A, Ottersbach K, Vassiliou GS, Olivier J, Wong JW, Göttgens B, Huntly BJ, Pimanda JE.  Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.  Blood. 2013 Mar 21;121(12):2289-300.

23.  Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM.  Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.  Mol Cancer. 2013 Mar 7;12(1):19.

22.  de Wit M, Ortner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K.  Management of Cytotoxic Extravasation - ASORS Expert Opinion for Diagnosis, Prevention and Treatment.  Onkologie. 2013;36(3):127-35.

21.  Kleger A, Schnell J, Essig A, Wagner M, Bommer M, Seufferlein T, Härter G.  Fecal Transplant in Refractory Clostridium difficile Colitis.  Dtsch Arztebl Int. 2013 Feb;110(7):108-15.

20.  Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong G, Kunjamma RB, Ren H, He C, Wang C, Elkahloun A, Valk P, Doehner K, Neilly MB, Bullinger L, Delwel R, Lowenberg B, Liu PP, Morgan R, Rowley JD, Yuan C, Chen J.  PBX3 is an important cofactor of HOXA9 in leukemogenesis.  Blood. 2013 Feb 21;121(8):1422-31.

19.  Jebaraj BM, Kienle D, Lechel A, Mertens D, Heuberger M, Ott G, Rosenwald A, Barth TF, Möller P, Zenz T, Döhner H, Stilgenbauer S.  Telomere length in mantle cell lymphoma.  Blood. 2013 Feb 14;121(7):1184-7.   18.  Garding A, Bhattacharya N, Haebe S, Mueller F, Weichenhan D, Idler I, Ickstadt K, Stilgenbauer S, Mertens D.  TCL1A and ATM are coexpressed in chronic lymphocytic leukemia cells without deletion of 11q.  Haematologica. 2013 Feb;98(2):269-73.

17.  Bommert KS, Effenberger M, Leich E, Küspert M, Murphy D, Langer C, Janz S, Moll R, Motto A, Rosenwald A, Bargou R, Bommert K.  The feed-forward loop between YB-1 and MYC is essential for Multiple Myeloma cell survival.  Leukemia. 2013 Feb;27(2):441-50.

16.  Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L.  Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.  Leukemia. 2013 Feb;27(2):353-61.

15.  Leich E, Weißbach S, Klein H-U, Grieb T, Pischimarov J, Stühmer S, Chatterjee M, Steinbrunn T, Langer C, Eilers M, Einsele, H, *Bargou R, and *Rosenwald A:  Multiple Myeloma is Affected by Multiple and Heterogeneous Somatic Mutations in Adhesion- and Receptor Tyrosine Kinase Signaling Molecules.  Blood Cancer J. 2013 Feb 8;3:e102. (*equal contribution).

14.  Schlenk RF, Döhner K, Döhner H.  [Acute myeloid leukemia : Genetic diagnostics and molecular therapy.]  Internist (Berl). 2013 Feb;54(2):171-8. German.   13.  Salaverria I1, Martin-Guerrero I, Burkhardt B, Kreuz M, Zenz T, Oschlies I, Arnold N, Baudis M, Bens S, García-Orad A, Lisfeld J, Schwaenen C, Szczepanowski M, Wessendorf S, Pfreundschuh M, Trümper L, Klapper W, Siebert R.  High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.  Genes Chromosomes Cancer. 2013 Feb;52(2):150-5.

12.  Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K.  Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).  Blood. 2013 Jan 3;121(1):170-7.

11.  Fernández-Sáiz V, Targosz B, Lemeer S, Eichner R, Langer C, Bullinger L, Reiter C, Slotta-Huspenina J, Schroeder S, Knorn A, Kurutz J, Peschel C, Pagano M, Kuster B, Bassermann F.  SCFFbxo9 and CK2direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma.  Nat Cell Biol. 2013 Jan;15(1):72-81.

10.  Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Farhadi Sartangi N, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD.  FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and iImply the clinical use of tyrosine kinase inhibitors.  PLoS One. 2013;8(1):e53190.

9.  Wei QX, Claus R, Hielscher T, Mertens D, Raval A, Oakes CC, Tanner SM, de la Chapelle A, Byrd JC, Stilgenbauer S, Plass C.  Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia.  PLoS One. 2013;8(1):e55261.

8.  Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Döhner K, Vasioukhin V, Fischer T, Armstrong SA.  The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.  J Exp Med. 2013 Jan 14;210(1):15-22.

7.  Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S.  CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR? signaling.  J Clin Invest. 2013 Jan 2;123(1):299-314.

6.  Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A.  90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.  J Clin Oncol. 2013 Jan 20;31(3):308-13.

5.  Hofmann S, Götz M, Schneider V, Guiallaume P, Bunjes D, Döhner H, Wiesneth M, Greiner J.  Donor lymphocyte infusion polyspecific CD8+ T cell responses with concurrent molecular remission in AML with NPM1 mutation.  J Clin Oncol. 2013 Jan 20;31(3):e44-7.

4.  Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn WM, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IGH, Berna Beverloo H, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Krauter J, Ganser A, Valk PJM, Löwenberg B, Döhner K, Döhner H*, Delwel R*  Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian AMLSG and Dutch-Belgian HOVON groups.  J Clin Oncol. 2013 Jan 1;31(1):95-103. (* equal contribution)   3.  Sun SM, Rockova V, Bullinger L, Dijkstra MK, Döhner H, Löwenberg B, Jongen-Lavrencic M.  The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.  Leukemia. 2013 Jan;27(1):100-6.

2.  Lin K, Lane B, Carter A, Johnson GG, Onwuazor O, Oates M, Zenz T, Stilgenbauer S, Atherton M, Douglas A, Ebrahimi B, Sherrington PD, Pettitt AR.  The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.  Br J Haematol. 2013 Jan;160(1):53-62.

1.  Herzberg PY1, Lee SJ, Heussner P, Mumm FH, Hilgendorf I, von Harsdorf S, Hemmati P, Rieger K, Greinix HT, Freund M, Holler E, Wolff D.  Personality influences quality-of-life assessments in adult patients after allogeneic hematopoietic SCT: results from a joint evaluation of the prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center.  Bone Marrow Transplant. 2013 Jan;48(1):129-34.  © 2017 Universitätsklinikum Ulm